ClinicalTrials.Veeva

Menu
Southern Specialty Research | Flowood, MS logo

Southern Specialty Research | Flowood, MS

Research site
About
Advancing medicine, improving lives

Site insights

Top conditions

Top treatments

Mitapivat
Concizumab
AG-348
Osivelotor
Crizanlizumab
marstacimab
Emicizumab
Anumigilimab
Crovalimab
Rilzabrutinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Wendy Thomson

Verified by this site

Active trials

8 of 10 total trials

A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.

Enrolling
Sickle Cell Disease
Drug: Osivelotor

This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in s...

Active, not recruiting
Sickle Cell Disease
Other: Mitapivat-matching placebo
Drug: Mitapivat

This is an open-label, multicenter study evaluating the efficacy and safety of marstacimab prophylaxis in approximately 95 male and female adolescent...

Enrolling
Hemophilia A or B
Drug: marstacimab

The primary objective of this study is to determine the effect of mitapivat versus placebo on the need for transfusions in subjects with SCD.

Enrolling
Sickle Cell Disease
Drug: Mitapivat
Drug: Mitapivat Matched Placebo

A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo...

Enrolling
Sickle Cell Disease
Biological: Crizanlizumab
Drug: Placebo

This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis.This...

Enrolling
Hemophilia A
Biological: Antithrombin concentrate (ATIIIC)
Biological: Emicizumab

This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered sub...

Enrolling
Sickle Cell Disease
Biological: Anumigilimab
Drug: Placebo
Locations recently updated

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by...

Enrolling
Sickle Cell Disease
Drug: Rilzabrutinib
Drug: Placebo

Trial sponsors

Agios Pharmaceuticals logo
Pfizer logo
Sanofi logo
CSL Behring logo
Novartis logo
Novo Nordisk logo
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems